Inhibrx Biosciences (INBX) Change in Accured Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has reported Change in Accured Expenses for 3 consecutive years, with -$1.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Change in Accured Expenses changed N/A year-over-year to -$1.4 million; the TTM figure through Dec 2025 stood at -$4.4 million (down 112.15% YoY), while the FY2025 annual figure was -$4.4 million, down 112.15% from the prior year.
• Change in Accured Expenses advanced to -$1.4 million in Q4 2025 per INBX's latest filing, from -$1.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $21.8 million in Q2 2024 and bottomed at -$4.3 million in Q2 2025.
• Historically, Change in Accured Expenses has averaged $6.1 million across 3 years, with a median of $6.0 million in 2024.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses declined 5.05% — and 2025, when it sank 125.12%.
• Inhibrx Biosciences' Change in Accured Expenses stood at $17.4 million in 2023, then tumbled by 65.33% to $6.0 million in 2024, then plunged by 123.78% to -$1.4 million in 2025.
• Business Quant data shows INBX's Change in Accured Expenses at -$1.4 million in Q4 2025, -$1.5 million in Q3 2025, and -$4.3 million in Q2 2025.